JP5540101B2 - ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法 - Google Patents

ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法 Download PDF

Info

Publication number
JP5540101B2
JP5540101B2 JP2012530282A JP2012530282A JP5540101B2 JP 5540101 B2 JP5540101 B2 JP 5540101B2 JP 2012530282 A JP2012530282 A JP 2012530282A JP 2012530282 A JP2012530282 A JP 2012530282A JP 5540101 B2 JP5540101 B2 JP 5540101B2
Authority
JP
Japan
Prior art keywords
triazol
isopropyl
dihydrobenzo
oxazepine
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012530282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505917A (ja
JP2013505917A5 (enExample
Inventor
二コール ブラキエール，
スティーヴン ドゥ，
ダネット ダドリー，
エイドリアン ジェイ． フォークス，
ロバート ヒールド，
ティモシー ヘフロン，
マーク ジョーンズ，
アレクサンドル コレスニコフ，
チュディ ンドゥバク，
アラン ジー． オリヴェロ，
スティーヴン プライス，
スティーヴン ステイベン，
ラン ワン，
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5540101(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2013505917A publication Critical patent/JP2013505917A/ja
Publication of JP2013505917A5 publication Critical patent/JP2013505917A5/ja
Application granted granted Critical
Publication of JP5540101B2 publication Critical patent/JP5540101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2012530282A 2009-09-28 2010-09-27 ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法 Active JP5540101B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24638109P 2009-09-28 2009-09-28
US61/246,381 2009-09-28
US33068510P 2010-05-03 2010-05-03
US61/330,685 2010-05-03
PCT/EP2010/064208 WO2011036280A1 (en) 2009-09-28 2010-09-27 Benzoxazepin pi3k inhibitor compounds and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013228826A Division JP5625101B2 (ja) 2009-09-28 2013-11-01 ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法

Publications (3)

Publication Number Publication Date
JP2013505917A JP2013505917A (ja) 2013-02-21
JP2013505917A5 JP2013505917A5 (enExample) 2013-12-19
JP5540101B2 true JP5540101B2 (ja) 2014-07-02

Family

ID=43037239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012530282A Active JP5540101B2 (ja) 2009-09-28 2010-09-27 ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法
JP2013228826A Active JP5625101B2 (ja) 2009-09-28 2013-11-01 ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013228826A Active JP5625101B2 (ja) 2009-09-28 2013-11-01 ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法

Country Status (31)

Country Link
US (7) US8242104B2 (enExample)
EP (3) EP2483278B1 (enExample)
JP (2) JP5540101B2 (enExample)
KR (1) KR101428346B1 (enExample)
CN (2) CN104744491B (enExample)
AR (1) AR078187A1 (enExample)
AU (1) AU2010299816C1 (enExample)
BR (1) BR112012006807A2 (enExample)
CA (1) CA2772691C (enExample)
CL (1) CL2012000754A1 (enExample)
CO (1) CO6491026A2 (enExample)
CR (1) CR20120121A (enExample)
DK (1) DK2483278T3 (enExample)
EC (1) ECSP12011755A (enExample)
ES (2) ES2444779T3 (enExample)
HR (1) HRP20140229T1 (enExample)
IL (2) IL217558A (enExample)
MA (1) MA33531B1 (enExample)
MX (1) MX2012003591A (enExample)
MY (2) MY184074A (enExample)
NZ (1) NZ597833A (enExample)
PE (1) PE20121025A1 (enExample)
PL (1) PL2483278T3 (enExample)
PT (1) PT2483278E (enExample)
RS (1) RS53164B (enExample)
RU (2) RU2654068C1 (enExample)
SG (1) SG10201405049RA (enExample)
SI (1) SI2483278T1 (enExample)
TW (1) TWI423980B (enExample)
WO (1) WO2011036280A1 (enExample)
ZA (1) ZA201202199B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509611A (ja) * 2011-03-21 2014-04-21 エフ．ホフマン−ラ ロシュ アーゲー ＰＩ３Ｋｐ１１０δに選択的なベンゾオキサゼピン化合物及び使用方法

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2464645T (lt) 2009-07-27 2017-10-25 Gilead Sciences, Inc. Kondensuoti heterocikliniai junginiai, kaip jonų kanalų moduliatoriai
CA2772691C (en) * 2009-09-28 2017-10-03 F. Hoffmann-La Roche Ag Benzoxazepin pi3k inhibitor compounds and methods of use
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
NZ604478A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
EP2707361B1 (en) 2011-05-10 2017-08-23 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (enExample) * 2011-07-01 2018-04-28
JP2015507001A (ja) * 2012-02-17 2015-03-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三環式化合物及びその使用方法
NZ702244A (en) * 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
SG10201805807PA (en) 2012-06-26 2018-08-30 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN102775395A (zh) * 2012-07-12 2012-11-14 江苏七洲绿色化工股份有限公司 一种丙环唑的制备方法及丙环唑中间体
AU2013299922B2 (en) * 2012-08-07 2018-06-21 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
CA2897618A1 (en) * 2013-03-13 2014-09-18 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
AU2014365079B2 (en) * 2013-12-16 2017-07-06 F. Hoffmann-La Roche Ag Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
AU2015228859A1 (en) 2014-03-13 2016-07-07 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
US10214501B2 (en) 2015-02-02 2019-02-26 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
ES2770128T3 (es) * 2015-04-30 2020-06-30 Recordati Ag Derivados de pirazol tricíclicos condensados útiles para modular los receptores farnesoide x
WO2016205334A1 (en) 2015-06-16 2016-12-22 Vascular Strategies Llc Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
US20160375033A1 (en) 2015-06-29 2016-12-29 Genentech, Inc. Methods of treatment with taselisib
CN111848643A (zh) * 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
MY195002A (en) 2015-07-02 2022-12-30 Hoffmann La Roche Benzoxazepin oxazolidinone compounds and methods of use
JP6873977B2 (ja) * 2015-09-08 2021-05-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 三環式ｐｉ３ｋ阻害化合物及び使用方法
US9721369B2 (en) * 2015-09-15 2017-08-01 Facebook, Inc. Systems and methods for utilizing multiple map portions from multiple map data sources
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
MX2019003714A (es) 2016-09-29 2019-06-24 Bayer Cropscience Ag Novedosos derivados de imidazolilmetilo 5-sustituidos.
CA3044500A1 (en) * 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
CN114984206A (zh) 2017-03-02 2022-09-02 基因泰克公司 Her2阳性乳腺癌的辅助治疗
EP3615541B1 (en) 2017-04-28 2025-03-19 F. Hoffmann-La Roche AG Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
ES2947411T3 (es) * 2017-10-26 2023-08-08 Xynomic Pharmaceuticals Inc Sales cristalinas de un campo inhibidor de quinasa B-RAF
CN110785423B (zh) * 2018-05-30 2022-07-26 江苏豪森药业集团有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
CN114599656A (zh) * 2019-11-04 2022-06-07 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
KR20220097466A (ko) * 2019-11-04 2022-07-07 베타 파머수티컬 컴퍼니 리미티드 이미다졸리디논류 화합물 및 이들의 제조방법과 용도
CA3159094A1 (en) * 2019-11-25 2021-06-03 Shanghai Hansoh Biomedical Co., Ltd. Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof
JP7652935B2 (ja) * 2021-05-03 2025-03-27 山東軒竹医薬科技有限公司 三環式ユビキチン特異的プロテアーゼ１阻害剤及びその使用
JP2024520920A (ja) * 2021-05-13 2024-05-27 貝達薬業股▲ふん▼有限公司 イミダゾリジノン類化合物の多形体、調製方法及びその使用
IL308457A (en) 2021-05-28 2024-01-01 Genentech Inc A process for preparing benzoxazepine oxazolidinone compounds
CN120202205A (zh) * 2022-11-17 2025-06-24 微境生物医药科技(上海)有限公司 三并环类PI3Kα抑制剂及其制备方法和医药用途
CN116003280B (zh) * 2022-12-30 2024-11-19 合肥工业大学 一种芳基甲酰胺类化合物的光化学合成方法
WO2025082533A1 (zh) * 2023-10-21 2025-04-24 上海轶诺药业有限公司 一种稠环化合物及其制备和应用
WO2025237374A1 (zh) * 2024-05-16 2025-11-20 微境生物医药科技(上海)有限公司 PI3Kα抑制剂及其制备方法和医药用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB8504702D0 (en) 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
KR0126300B1 (ko) 1992-12-28 1997-12-26 나이토 하루오 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
WO1997019087A1 (en) 1995-11-17 1997-05-29 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19908533A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908538A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
WO2001064675A1 (en) 2000-03-03 2001-09-07 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
EP1355875A1 (en) 2001-02-02 2003-10-29 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
CA2492922A1 (en) 2002-07-19 2004-01-29 Pharmacia Corporation Substituted thiophene carboxamide compounds for the treatment of inflammation
EP1594495A1 (en) * 2003-02-07 2005-11-16 Warner-Lambert Company LLC Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
CA2571807A1 (en) * 2004-07-01 2006-01-19 Merck & Co., Inc. Mitotic kinesin inhibitors
KR20070064660A (ko) 2004-10-07 2007-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ｐｉ３ 키나제
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
GB0610866D0 (en) * 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
WO2008014483A1 (en) * 2006-07-28 2008-01-31 Alcan Packaging Flexible France Coextruded film with polylactic acid (pla) and ethylene vinyl acetate (eva)
US8877791B2 (en) 2006-08-04 2014-11-04 Beth Israel Deaconess Medical Center, Inc. Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
KR101578674B1 (ko) * 2006-12-29 2015-12-18 아비에 도이치란트 게엠베하 운트 콤파니 카게 카복스아미드 화합물 및 칼페인 억제제로서의 이의 용도
AU2008302703B2 (en) 2007-09-19 2013-11-07 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
CA2719032C (en) * 2008-03-31 2016-11-08 Steven Do Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
WO2010043676A1 (en) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
US8263633B2 (en) * 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
CA2772691C (en) * 2009-09-28 2017-10-03 F. Hoffmann-La Roche Ag Benzoxazepin pi3k inhibitor compounds and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509611A (ja) * 2011-03-21 2014-04-21 エフ．ホフマン−ラ ロシュ アーゲー ＰＩ３Ｋｐ１１０δに選択的なベンゾオキサゼピン化合物及び使用方法

Also Published As

Publication number Publication date
MA33531B1 (fr) 2012-08-01
HK1174629A1 (en) 2013-06-14
RU2654068C1 (ru) 2018-05-16
CO6491026A2 (es) 2012-07-31
US20130079331A1 (en) 2013-03-28
WO2011036280A1 (en) 2011-03-31
KR20120065431A (ko) 2012-06-20
IL217558A0 (en) 2012-02-29
CN102762576B (zh) 2015-04-22
US8343955B2 (en) 2013-01-01
JP2014070075A (ja) 2014-04-21
ES2570569T3 (es) 2016-05-19
CA2772691A1 (en) 2011-03-31
SI2483278T1 (sl) 2014-03-31
EP2711368B1 (en) 2016-03-23
AU2010299816B2 (en) 2015-11-12
TWI423980B (zh) 2014-01-21
DK2483278T3 (da) 2014-01-13
CL2012000754A1 (es) 2012-09-07
ZA201202199B (en) 2013-01-30
CR20120121A (es) 2012-06-01
AR078187A1 (es) 2011-10-19
CN102762576A (zh) 2012-10-31
MY184074A (en) 2021-03-17
MY160064A (en) 2017-02-15
PE20121025A1 (es) 2012-08-06
US20110076292A1 (en) 2011-03-31
AU2010299816A1 (en) 2012-02-02
US20120244149A1 (en) 2012-09-27
SG10201405049RA (en) 2014-10-30
JP2013505917A (ja) 2013-02-21
US20140288047A1 (en) 2014-09-25
US8242104B2 (en) 2012-08-14
RU2600927C2 (ru) 2016-10-27
US20160052933A1 (en) 2016-02-25
JP5625101B2 (ja) 2014-11-12
HRP20140229T1 (hr) 2014-04-11
US9670228B2 (en) 2017-06-06
KR101428346B1 (ko) 2014-08-07
US20170081341A1 (en) 2017-03-23
IL239081A0 (en) 2015-07-30
US9198918B2 (en) 2015-12-01
NZ597833A (en) 2014-01-31
RU2012117398A (ru) 2013-11-10
ES2444779T3 (es) 2014-02-26
CN104744491B (zh) 2017-07-11
MX2012003591A (es) 2012-04-19
CA2772691C (en) 2017-10-03
EP2845592A1 (en) 2015-03-11
EP2711368A1 (en) 2014-03-26
CN104744491A (zh) 2015-07-01
US20140058098A1 (en) 2014-02-27
ECSP12011755A (es) 2012-05-30
AU2010299816C1 (en) 2018-02-01
IL217558A (en) 2015-06-30
BR112012006807A2 (pt) 2020-11-03
EP2483278B1 (en) 2013-12-25
TW201127844A (en) 2011-08-16
US9546178B2 (en) 2017-01-17
US8785626B2 (en) 2014-07-22
US8586574B2 (en) 2013-11-19
EP2483278A1 (en) 2012-08-08
RS53164B (sr) 2014-06-30
PL2483278T3 (pl) 2014-05-30
PT2483278E (pt) 2014-03-05
HK1211929A1 (en) 2016-06-03
IL239081B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
JP5540101B2 (ja) ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法
JP5546636B2 (ja) ベンゾキセピンｐｉ３ｋ阻害剤化合物及び使用方法
AU2015252149B2 (en) Benzoxazepin PI3K inhibitor compounds and methods of use
HK1174629B (en) Benzoxazepin pi3k inhibitor compounds and methods of use
HK1211929B (en) Benzoxazepin pi3k inhibitor compounds and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131101

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20131101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131121

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20131122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140401

R150 Certificate of patent or registration of utility model

Ref document number: 5540101

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140501

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250